scholarly journals Performance of a HER2 testing algorithm specific for p53‐abnormal endometrial cancer

2021 ◽  
Author(s):  
Lisa Vermij ◽  
Naveena Singh ◽  
Alicia Leon‐Castillo ◽  
Nanda Horeweg ◽  
Jan Oosting ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Her2 Testing ◽  
Testing Algorithm

HER2 testing in esophageal adenocarcinoma (EAC) using parallel tissue-based methods.

2013 ◽  
Vol 31 (4_suppl) ◽  
pp. 2-2 ◽  
Author(s):  
Harry H. Yoon ◽  
Qian Shi ◽  
William R. Sukov ◽  
Christopher A. Sattler ◽  
Anne E. Wiktor ◽  
...  
Keyword(s):  
Gene Amplification ◽  
Predictive Value ◽  
Gastroesophageal Junction ◽  
Her2 Amplification ◽  
Her2 Protein ◽  
Her2 Testing ◽  
Blinded Manner ◽  
Testing Algorithm ◽  
Background Testing

2 Background: Testing for HER2 in EAC has become routine given its ability to predict benefit from HER2-targeted therapy. HER2 protein analysis by immunohistochemistry (IHC) is more rapid and generally less expensive than assessment of gene amplification by fluorescence in situ hybridization (FISH). However, the accuracy of IHC for predicting HER2 amplification has not been examined in a large EAC cohort. Methods: Surgical EAC specimens were examined from 675 patients who underwent curative resection at a single institution without preoperative therapy. Tumors were located in the esophagus (47%) or gastroesophageal junction (53%); most were node-positive (73%). Every tumor was evaluated by IHC in parallel with FISH in a blinded manner using FDA-approved assays. A consensus IHC score was determined by 2 pathologists using tumor-specific criteria (negative, 0 or 1+; equivocal, 2+; positive, 3+). Gene amplification by FISH was defined as a HER2/CEP17ratio ≥ 2. Results: HER2 amplification was detected in 89% of IHC 3+ cases, 13% of IHC 2+ cases, and 4% of IHC 0-1+ cases (Table). Accordingly, using FISH as the reference standard, the positive predictive value (PPV) of a positive IHC test (3+) was 89% (79/89 [95% CI 82%-95%]), and the negative predictive value of a negative IHC test (0-1+) was 96% (401/417 [94%-98%]). Importantly, the PPV of an equivocal IHC score (2+) for detecting HER2 amplification was 13% (22/169 [8%-18%]). Conclusions: In the largest study to date comparing HER2 testing methods in EAC, a negative IHC result (0 or 1+) nearly excludes the presence of gene amplification by FISH. Whereas a positive IHC result (3+) strongly predicts for the presence of amplification, an equivocal IHC result (2+) is a weak predictor. These findings in EAC support a HER2 testing algorithm where IHC is used for initial screening and FISH testing is restricted to cases with equivocal IHC results. [Table: see text]

Comparisons among calculations of cortisol output in women undergoing surgery for suspected endometrial cancer

2013 ◽  
Author(s):  
Timothy Sannes ◽  
Seema Patidar ◽  
Stephanie Smith ◽  
Sally Jensen ◽  
Linda Morgan ◽  
...  
Keyword(s):  
Endometrial Cancer
Sign in / Sign up

Export Citation Format

Share Document